Roche announced results from the international phase III study PRIMA1, which show that MabThera (rituximab) maintenance therapy can significantly increase the time until the disease progresses in newly-treated patients with advanced follicular lymphoma, a common and slow-developing but incurable form

A long-term study has found that men with low- grade, slow-growing prostate cancer who are managed with active surveillance and no radical treatment have an extremely high survival rate.

HistoRx today announced that the Company's proprietary AQUA technology, an automated image analysis platform based on tissue-based quantitative immunofluorescence, was noted in a recent National Comprehensive Cancer Network (NCCN) Task Force Report on hormone receptor testing in breast cancer as

A radiation breakthrough to treat breast cancer patients in one day, as opposed to the current average of six weeks, has arrived at Cancer Treatment Centers of America(R) (CTCA) in Philadelphia. CTCA will become the first in the country to

After four years of research, a new test will help identify cancer in women with ovarian cysts before surgery. Until the OVA1 blood test was created, a precise diagnosis before surgery wasn't possible, said Dr. Frederick R. Ueland, associate professor

After losing her mother to cancer, Shelia Weeks, 61, was advised by her doctor to begin receiving mammograms when she was 36. Her mother's cancer was found in her liver, but started in her breast. There was no widespread detection

Synta Pharmaceuticals Corp, a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a